-+ 0.00%
-+ 0.00%
-+ 0.00%

Thalia Therapeutics Unit Signs Clinical Trial Deal for Acute Myeloid Leukemia Treatment Study

MT Newswires·11/09/2026 05:25:38
Listen to the news
05:25 AM EST, 11/09/2026 (MT Newswires) -- Thalia Therapeutics (THAT.L) unit Sanmirna Therapeutics signed a clinical trial agreement for the ongoing phase 1 study of miRisten, a potential treatment for relapsed or refractory acute myeloid leukemia. The UK-listed biotechnology company said Monday that the agreement with US-based City of Hope will allow the parties access to information related to the dose escalation trial, including results and budget confirmation. City of Hope discovered miRisten and licensed the intellectual property rights to Sanmirna. Interim results are expected to be released in the fourth quarter of 2026, with topline data slated for the first half of 2027.